Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MNRP1685A · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MNRP1685A | DRUG | Escalating intravenous dose |
Inclusion Criteria: * Age ≥ 18 years * Incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior regimen * Evaluable or measurable disease per RECIST (in certain circumstances, prostate or ovarian cancer patients with non-measura...
MNRP1685A is an investigational small molecule developed by Roche Holding AG for the treatment of locally advanced or metastatic solid tumors. It was studied in a single Phase 1 clinical trial and is not an approved therapy. The program enrolled 35 patients with solid cancers.
MNRP1685A was studied for the treatment of locally advanced or metastatic solid tumors. It was evaluated in one Phase 1 trial that enrolled 35 adult patients with solid cancers. The trial is completed, and MNRP1685A is not an approved treatment for any indication.
MNRP1685A was developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche sponsored the Phase 1 study of the drug in patients with locally advanced or metastatic solid tumors.
MNRP1685A is in Phase 1 development. It has been tested in a single Phase 1 clinical trial in patients with locally advanced or metastatic solid tumors, and that trial is now completed. MNRP1685A is investigational and has not been approved by the FDA.
MNRP1685A was studied in one clinical trial, NCT00747734, titled A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors. The Phase 1 trial enrolled 35 patients aged 18 years and older and is completed. No trials of MNRP1685A are currently active.
The Phase 1 trial of MNRP1685A, NCT00747734, was an uncontrolled study. It was not randomized and not double blinded, and it enrolled 35 patients with locally advanced or metastatic solid tumors. The study is completed.